ZIOPHARM Oncology Inc. (ZIOP) Given Consensus Recommendation of “Hold” by Brokerages
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has earned an average recommendation of “Hold” from the six research firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $12.58.
Several analysts have commented on the stock. ValuEngine raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Monday, August 28th. BidaskClub raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. HC Wainwright reissued a “buy” rating and set a $9.50 price target on shares of ZIOPHARM Oncology in a research report on Tuesday, November 7th. Finally, Zacks Investment Research raised shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research report on Friday, November 10th.
Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) opened at $4.36 on Tuesday. ZIOPHARM Oncology has a 1 year low of $4.03 and a 1 year high of $7.88.
In related news, CEO Laurence James Neil Cooper acquired 6,440 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was purchased at an average cost of $4.68 per share, with a total value of $30,139.20. Following the transaction, the chief executive officer now directly owns 1,083,731 shares of the company’s stock, valued at approximately $5,071,861.08. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 10.40% of the company’s stock.
Several institutional investors have recently made changes to their positions in ZIOP. Chevy Chase Trust Holdings Inc. purchased a new position in shares of ZIOPHARM Oncology in the 3rd quarter valued at approximately $104,000. Amalgamated Bank raised its position in shares of ZIOPHARM Oncology by 12.9% in the 2nd quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 1,924 shares during the last quarter. Oppenheimer & Co. Inc. raised its position in shares of ZIOPHARM Oncology by 50.0% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 6,000 shares during the last quarter. BB&T Securities LLC purchased a new position in shares of ZIOPHARM Oncology in the 2nd quarter valued at approximately $112,000. Finally, Adell Harriman & Carpenter Inc. purchased a new position in shares of ZIOPHARM Oncology in the 3rd quarter valued at approximately $141,000. 40.25% of the stock is owned by hedge funds and other institutional investors.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.